CN118488853A - 组合疗法 - Google Patents
组合疗法 Download PDFInfo
- Publication number
- CN118488853A CN118488853A CN202280066217.5A CN202280066217A CN118488853A CN 118488853 A CN118488853 A CN 118488853A CN 202280066217 A CN202280066217 A CN 202280066217A CN 118488853 A CN118488853 A CN 118488853A
- Authority
- CN
- China
- Prior art keywords
- dose
- glp
- agonist
- actrii receptor
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163238068P | 2021-08-27 | 2021-08-27 | |
| US63/238,068 | 2021-08-27 | ||
| US202263301012P | 2022-01-19 | 2022-01-19 | |
| US63/301,012 | 2022-01-19 | ||
| US202263333351P | 2022-04-21 | 2022-04-21 | |
| US63/333,351 | 2022-04-21 | ||
| PCT/US2022/075545 WO2023028606A1 (en) | 2021-08-27 | 2022-08-26 | Combination therapies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118488853A true CN118488853A (zh) | 2024-08-13 |
Family
ID=83897998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280066217.5A Pending CN118488853A (zh) | 2021-08-27 | 2022-08-26 | 组合疗法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240325530A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4392137A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024532619A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240099142A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118488853A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022332306A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3229355A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL310919A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024002467A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202323296A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023028606A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4121078A4 (en) | 2020-03-20 | 2024-08-14 | Keros Therapeutics, Inc. | ACTIVIN RECEPTOR TYPE II CHIMERAS AND METHODS OF USE THEREOF |
| EP4121088A4 (en) | 2020-03-20 | 2024-07-03 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| SI4408840T1 (sl) | 2021-09-27 | 2025-12-31 | Terns Pharmaceuticals, Inc. | Benzimidazolne karboksilne kisline kot agonisti GLP-1R |
| US12024507B2 (en) | 2021-10-25 | 2024-07-02 | Terns Pharmaceuticals, Inc. | Compounds as GLP-1R agonists |
| EP4466288A4 (en) * | 2022-01-19 | 2026-02-25 | Versanis Bio Inc | ACTRII ANTIBODY-BASED TREATMENTS |
| AU2023224854A1 (en) | 2022-02-23 | 2024-10-03 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| EP4577301A1 (en) | 2022-08-26 | 2025-07-02 | Versanis Bio, Inc. | Actrii antibody fixed unit dose treatments |
| PE20252787A1 (es) | 2023-04-07 | 2025-12-22 | Terns Pharmaceuticals Inc | Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica |
| IL326224A (en) | 2023-07-31 | 2026-03-01 | Sixpeaks Bio Ag | Antibody conjugates and fusion proteins |
| WO2025106773A1 (en) * | 2023-11-17 | 2025-05-22 | Apnimed, Inc. (Delaware) | Methods and compositions for treating sleep apnea with a combination of a glp-1 agonist and a second active agent |
| IL330385A (en) * | 2023-12-29 | 2026-08-01 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Antibody-polypeptide conjugate and its pharmaceutical use |
| WO2025147483A1 (en) * | 2024-01-02 | 2025-07-10 | Keros Therapeutics, Inc. | Methods of using activin receptor type ii chimeras |
| WO2025183966A1 (en) | 2024-02-28 | 2025-09-04 | Versanis Bio, Inc. | Actrii antibodies with extended half life |
| WO2025217521A1 (en) * | 2024-04-12 | 2025-10-16 | Jnana Therapeutics Inc. | Treating chronic kidney disease with a combination of a slc6a19 inhibitor and a glp-1 agonist |
| WO2025247309A1 (zh) * | 2024-05-31 | 2025-12-04 | 上海齐鲁制药研究中心有限公司 | 融合蛋白分子及其应用 |
| WO2026128614A1 (en) * | 2024-12-10 | 2026-06-18 | Supercede Therapeutics, Inc. | Activin receptor type ii inhibitors for preventing or treating obesity and related disorders |
| EP4785960A1 (en) | 2025-01-31 | 2026-08-05 | SixPeaks Bio AG | Glp-1 antibody conjugates |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2655877T3 (es) | 2009-04-27 | 2018-02-22 | Novartis Ag | Composiciones y métodos para aumentar el crecimiento muscular |
| JOP20190152A1 (ar) | 2016-12-21 | 2019-06-20 | Novartis Ag | مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة |
| WO2018129395A1 (en) * | 2017-01-06 | 2018-07-12 | Scholar Rock, Inc. | Methods for treating metabolic diseases by inhibiting myostatin activation |
-
2022
- 2022-08-26 EP EP22797198.3A patent/EP4392137A1/en active Pending
- 2022-08-26 TW TW111132340A patent/TW202323296A/zh unknown
- 2022-08-26 CA CA3229355A patent/CA3229355A1/en active Pending
- 2022-08-26 IL IL310919A patent/IL310919A/en unknown
- 2022-08-26 KR KR1020247010022A patent/KR20240099142A/ko active Pending
- 2022-08-26 AU AU2022332306A patent/AU2022332306A1/en active Pending
- 2022-08-26 CN CN202280066217.5A patent/CN118488853A/zh active Pending
- 2022-08-26 MX MX2024002467A patent/MX2024002467A/es unknown
- 2022-08-26 WO PCT/US2022/075545 patent/WO2023028606A1/en not_active Ceased
- 2022-08-26 JP JP2024537306A patent/JP2024532619A/ja active Pending
-
2024
- 2024-02-26 US US18/587,617 patent/US20240325530A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240325530A1 (en) | 2024-10-03 |
| MX2024002467A (es) | 2024-05-20 |
| EP4392137A1 (en) | 2024-07-03 |
| WO2023028606A1 (en) | 2023-03-02 |
| AU2022332306A1 (en) | 2024-02-29 |
| CA3229355A1 (en) | 2023-03-02 |
| IL310919A (en) | 2024-04-01 |
| TW202323296A (zh) | 2023-06-16 |
| KR20240099142A (ko) | 2024-06-28 |
| JP2024532619A (ja) | 2024-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240325530A1 (en) | Combination therapies | |
| JP2024532619A5 (cg-RX-API-DMAC7.html) | ||
| CN120815164A (zh) | 使用gip/glp1共激动剂用于治疗的方法 | |
| JP2024521091A (ja) | 褐色脂肪生成を誘導する方法及び組成物 | |
| AU2020341135A1 (en) | Treatment of liver disease or disorder comprising ActRII receptor antagonists | |
| JP2023515771A (ja) | 強皮症および関連する疾病の処置のための方法 | |
| JP2008518941A (ja) | 大腸連続性を伴う短腸症候群患者の治療 | |
| US20260070992A1 (en) | Actrii antibody fixed unit dose treatments | |
| CN118055767A (zh) | 新颖的组合施用 | |
| EP2240195A1 (en) | Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic t lymphocyte-associated antigen 4 (ctla4) | |
| JP2025504453A (ja) | ActRII抗体治療 | |
| JP2023510609A (ja) | Glp-1および/またはglp-1類似体、ならびにインスリンおよび/またはインスリン類似体を含む併用療法 | |
| WO2023056297A1 (en) | Cd40l-specific tn3-derived scaffolds for the treatment and prevention of sjogren's syndrome | |
| KR20260013453A (ko) | 체중 관련 동반질환이 있거나 없는 과체중 또는 비만 성인의 치료 | |
| WO2025183966A1 (en) | Actrii antibodies with extended half life | |
| JP2023518645A (ja) | Glp-1の投薬レジメン | |
| RU2838150C1 (ru) | Лечение заболевания или нарушения со стороны печени, предусматривающее применение антагонистов рецепторов actrii | |
| US20230331859A1 (en) | Methods for treating short bowel syndrome and/or high output ostomy | |
| CN121969358A (zh) | 选择性雄激素受体调节剂(sarm)化合物在长期体重管理中的用途 | |
| WO2025245160A1 (en) | Myostatin-selective inhibitors for treating metabolic disorders | |
| CN118201629A (zh) | 用于治疗和预防干燥综合征的cd40l特异性tn3衍生的支架 | |
| Fukuda et al. | OR07-2 METABOLIC COMPLICATIONS REVEALED IN 42 PATIENTS WITH CHILDHOOD-ONSET ADULT GH DEFICIENCY AFTER THE CESSATION OF GH REPLACEMENT THERAPY FOR SHORT STATURE | |
| Cohen et al. | OR07-3 VALIDATION OF THE EFFICACY AND SAFETY OF IGF-BASED DOSE-TITRATION IN CHILDREN WITH GROWTH FAILURE ASSOCIATED WITH NON-GH-DEFICIENT, IGF-I DEFICIENCY: RESULTS OF CLINICAL TRIAL HGH 2147 ON BEHALF OF THE AMERICAN Norditropin® CLINICAL STUDIES GROUP | |
| Miyasaka | Etanercept and methotrexate for the treatment of rheumatoid arthritis | |
| Smyth et al. | trials tell us?[version 1; peer review: 2 approved] |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |